FDA's Office of Pharmaceutical Quality White Paper on the Economics of Quality Management Incentives
- Date
- August 1, 2025
- Category
US Regulations
- Description
The FDA's Office of Pharmaceutical Quality has released a new white paper: "Quality Management Initiatives in the Pharmaceutical Industry: An Economic Perspective".
This comprehensive analysis demonstrates that strategic investments in quality management initiatives deliver measurable returns for both companies and public health:
- Economic Returns: Companies can realise significant cost savings through reduced defects, decreased waste, and improved operational efficiency. Even incremental investments in quality management can yield positive returns.
- Public Health Benefits: Mature quality management practises help prevent drug shortages, strengthen supply chain reliability, and ensure consistent medication availability for patients. The paper quantifies the extensive costs of poor quality management - from direct manufacturing impacts to broader societal consequences.
- Scalable Implementation: The economic model shows that quality management investments are not "all-or-nothing" — companies can implement stepwise approaches tailored to their specific context and resource levels.
The white paper includes real-world case studies, economic modelling, and analysis of costs across manufacturers, patients, healthcare systems, and society. It reinforces FDA's commitment to encouraging mature quality management practises that benefit both business outcomes and patient care.